Acquired Immune Deficiency Syndrome
Conditions
Interventions
Queue one:Antiviral treatment of western medicine + artesunate tablet
Queue two:Antiviral treatment of western medicine + moxibustion method
Sponsors
China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Between the ages of 18 and 65, male and female; 2) the HIV antibody positive, by Western Blot confirmed test proof; 3) HAART treatment time is more than 1 year, and plasma HIV loads < 50 copies/ml is more than 18 months; 4) CD4 + T lymphocyte count < 300 cells/ul, or compared to the baseline growth < 20%; 5) voluntary to participate in this study, signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Serious opportunistic infection before entering the group is not controlled; 2) Within a month before into the group or other drugs is participating in clinical trials of patients; 3) Within a month before into the group of immune modulators therapy; 4) the WBC < 2 x 10^9/L, N <1.0 x 10^9/L, Hb < 90 g/L, PLT < 75 x 10^9/L, liver and kidney dysfunction, abnormal liver function refers to the AST/ALT or T-BIL reference cap of 2 or more times, kidney function abnormal creatinine clearance below normal); 5) combined hepatitis c, liver cirrhosis, syphilis patient; 6) pregnant or lactating women and women of childbearing age without adopting safe contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute Value of CD4+ cells;Immune Reconstruction Efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD8+, CD45RA+, CD45RO+, CD4+CD28+, CD8+CD38+, CD4+CD38+;Cell proliferation and apoptosis: CD4+ki67+/CD4+, CD8+ki67+/CD8+, mitochondrial membrane potential;clinical symptoms;WHO quality of life scale;Viral load; | — |
Countries
China
Contacts
Public ContactWang Jian
China Academy of Chinese Medical Sciences
Outcome results
None listed